Genomics of Drug Sensitivity in Cancer |
CGP-60474
|
Synonyms |
KIN001-019, CGP60474, CGP 60474
|
Targets |
CDK1,CDK2,CDK5,CDK7,CDK9, PKC
|
Target pathway |
Cell cycle
|
PubCHEM ID |
644215
|
Jsmol |
|
Download molecule |
644215
|
PUBCHEM IUPAC INCHI |
InChI=1S/C18H18ClN5O/c19-14-3-1-4-15(12-14)23-18-22-9-6-16(24-18)13-5-8-21-17(11-13)20-7-2-10-25/h1,3-6,8-9,11-12,25H,2,7,10H2,(H,20,21)(H,22,23,24)
|
Smiles |
ClC3(=CC(NC2(=NC(C1(=CC(=NC=C1)NCCCO))=CC=N2))=CC=C3)
|
Cluster number |
124
|
calculated LogS |
-4,828
|
Molecular weight |
355,828
|
calculated LogP |
3,284
|
H-Acceptors |
6
|
H-Donors |
3
|
Ro5 violations |
0
|
Druglikeness |
-1,7391
|
DrugScore |
0,37874278646608
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Fish Toxicity |
Low FHMT
|
Fish Toxicity2 |
1,7066
|
Rat Acute Toxicity |
2,1196
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2-
|
Caco-2 Permeability2 |
0,98
|
P-glycoprotein Substrate |
Non-substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor2 |
Non-inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Non-inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,4887
|
AMES Toxicity |
Non AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Non-substrate
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Non-required
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-3,4025
|